Immunicum's uplisting to Nasdaq Stockholm postponed

GOTHENBURG, Sweden, March 24, 2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, announced today that Nasdaq Stockholm's listing committee has postponed the decision on Immunicum's application for admission to trading. The committee noted that Immunicum has formalized and conformed its corporate governance and communication procedures to the additional requirements imposed on companies listed on Nasdaq Stockholm and  that the company needs to demonstrate that it will continue to apply them for a longer period before the committee can make a final decision on the company's application.

The company will announce the final decision from the listing committee following the communication of the decision, which is not expected before the third quarter of 2017.

About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com

For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Ph: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com

The Company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31
www.redeye.se

The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person set out above on March 24, 2017 at 4.35 pm CET